Tislelizumab,Sorafenib
BeiGene,bayer
['tislelizumab', 'beigene', '$bgne']
$bgne beigene announces data presentations at esmo 2022 including late-breaking oral presentation for tislelizumab in first-line unresectable hepatocellular cancer 45 seconds delayed.
Democratizing insights.

Not investment advice.